MedTrace Logo

Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris

NCT02525822 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2015-09-14

No results posted yet for this study

Summary

The primary objective of this study is to compare the safety and efficacy of once daily application of IDP-123 Lotion to Tazorac Cream, 0.1%, Vehicle Lotion, and Vehicle Cream in subjects with moderate to severe acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

IDP-123 Lotion

Investigational Product: IDP-123 Lotion

DRUG

Tazorac Cream, 0.1%,

Comparator Product: Tazorac Cream, 0.1%

DRUG

Vehicle Cream

Comparator Product: Vehicle Cream

DRUG

Vehicle Lotion

Comparator Product: Vehicle Lotion

Sponsors & Collaborators

  • Valeant Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Anya Loncaric, MS · Valeant Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-06-30
Completion
2016-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02525822 on ClinicalTrials.gov